Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.43 USD
−27.78 M USD
1.50 M USD
13.99 M
About Oncocyte Corporation
Sector
Industry
CEO
Joshua Riggs
Website
Headquarters
Irvine
Founded
2009
FIGI
BBG008P5VFV1
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OCX is 2.67 USD — it has increased by 7.84% in the past 24 hours. Watch Oncocyte Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oncocyte Corporation stocks are traded under the ticker OCX.
OCX stock has fallen by −8.33% compared to the previous week, the month change is a −14.06% fall, over the last year Oncocyte Corporation has showed a −35.18% decrease.
We've gathered analysts' opinions on Oncocyte Corporation future price: according to them, OCX price has a max estimate of 4.25 USD and a min estimate of 4.00 USD. Watch OCX chart and read a more detailed Oncocyte Corporation stock forecast: see what analysts think of Oncocyte Corporation and suggest that you do with its stocks.
OCX stock is 9.37% volatile and has beta coefficient of 0.24. Track Oncocyte Corporation stock price on the chart and check out the list of the most volatile stocks — is Oncocyte Corporation there?
Today Oncocyte Corporation has the market capitalization of 46.30 M, it has decreased by −1.79% over the last week.
Yes, you can track Oncocyte Corporation financials in yearly and quarterly reports right on TradingView.
Oncocyte Corporation is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
OCX earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.44 USD resulting in a 7.99% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Oncocyte Corporation earnings.
Oncocyte Corporation revenue for the last quarter amounts to 115.00 K USD, despite the estimated figure of 178.33 K USD. In the next quarter, revenue is expected to reach 101.67 K USD.
OCX net income for the last quarter is −13.49 M USD, while the quarter before that showed −4.53 M USD of net income which accounts for −197.86% change. Track more Oncocyte Corporation financial stats to get the full picture.
No, OCX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 46.00 employees. See our rating of the largest employees — is Oncocyte Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Oncocyte Corporation EBITDA is −21.57 M USD, and current EBITDA margin is −1.37 K%. See more stats in Oncocyte Corporation financial statements.
Like other stocks, OCX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oncocyte Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oncocyte Corporation technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oncocyte Corporation stock shows the sell signal. See more of Oncocyte Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.